Generic Name and Formulations:
Cefprozil 250mg, 500mg; tabs.
Various generic manufacturers
Indications for Cefprozil:
Susceptible mild to moderate infections, including pharyngitis/tonsillitis, secondary bacterial infection of acute bronchitis, acute bacterial exacerbation of chronic bronchitis, acute sinusitis, skin and skin structure, otitis media.
≥13yrs: Pharyngitis/tonsillitis: 500mg every 24hrs. Acute sinusitis: 250mg (mild) or 500mg (moderate to severe) every 12hrs. Bronchitis: 500mg every 12hrs. Skin and skin structure: 250mg every 12hrs or 500mg every 12–24hrs. All: for 10 days. CrCl<30mL/min: 50% of standard dose.
Otitis media: <6 months: not recommended; 6 months to 12yrs: 15mg/kg every 12hrs. Acute sinusitis: <6 months: not recommended; 6months to 12yrs: 7.5mg/kg (mild) or 15mg/kg (moderate to severe) every 12hrs. Pharyngitis/tonsillitis: <2yrs: not recommended; 2–12yrs: 7.5mg/kg every 12hrs. Skin and skin structure: <2yrs: not recommended; 2–12yrs: 20mg/kg every 24hrs. All: for 10 days.
Penicillin or other allergy. Renal impairment, reduce dose. Monitor renal function. GI disease (esp. colitis). Labor & delivery. Pregnancy (Cat.B). Nursing mothers.
Avoid diuretics, other nephrotoxic drugs, including aminoglycosides. Potentiated by probenecid. May cause false (+) Clinitest.
GI upset, elevated liver enzymes, dizziness.
Formerly known under the brand name Cefzil.
Clinical Pain Advisor Articles
- Chronic Neuropathic Pain Updated Classification by IASP for ICD-11
- Buprenorphine-Naloxone Found to Be More Cost-Effective Than Extended-Release Naltrexone
- Ultrasound-Guided C2 Coblation May Be Effective for Cervicogenic Headache
- Meta-Analysis of Opioid Treatment for Chronic Noncancer Pain
- Opioids Found to Increase Risk for Community-Acquired Pneumonia, Particularly in HIV
- Reviewing the Use of Buprenorphine in Perioperative Pain Management
- Early Physical Therapy for Musculoskeletal Pain May Reduce Opioid Use
- External Trigeminal Nerve Stimulation May Alleviate Migraine Pain
- IASP Updates Diagnosis Criteria for Chronic Primary Pain for ICD-11
- Galcanezumab Provides Persistent Preventive Effects in Episodic, Chronic Migraine
- Comparable Analgesia With Low-Dose IV Ketamine, Morphine for Acute Pain
- Benzodiazepines, if Prescribed, May Not Affect Methadone Treatment Retention
- When Opioid Prescribing Guidelines Become Rules
- IV Fluid Confers No Significant Treatment Effect on Migraine Pain
- American Headache Society Releases Position Statement on Novel Preventive and Acute Migraine Treatments